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Abstract: Cannabis sativa L. turned out to be a valuable source of chemical compounds of various 
structures, showing pharmacological activity. The most important groups of compounds include 
phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis 
multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), 
Parkinson's disease, Tourette's syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 
(COVID-19)), which has been proven so far, results from the affinity of these compounds predomi­
nantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CBj), type 
two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator- 
activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential 
channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in 
Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through 
the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology 
of compounds present in Cannabis extracts in the context of the current knowledge about their 
synergistic actions and the implications of clinical use in the treatment of selected diseases.
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1. Introduction
The history o f m any drugs currently  used in m edicine has its origins in p lant raw  
m aterials. M orphine, atropine, paclitaxel, and, recently, artem isinin are the m ost fam ous 
exam ples in the drug discovery process [1]. W ith the developm ent of analytical techniques 
and separation methods, it was possible to isolate individual compounds and, consequently, 
define their m olecular m echanism s of action by assessing their interactions w ith  selected 
receptors. Often, the therapeutic demand for com pounds of plant origin is enorm ous, and 
effective synthesis pathw ays have to be developed, as in the case of m orphine [2]. It took, 
how ever, m any years from  its d iscovery to a chem ical synthesis. A t the beginning of the 
nineteenth century, Friedrich Sertürner, for the first tim e in  history, isolated this alkaloid 
from  the opium  poppy (Papaver som niferum ) [3] . How ever, it w as not until over 100 years 
later that Sir Robert Robinson first proposed the correct morphine structure in 1925, which 
w as confirm ed by the first total synthesis of m orphine by  Gates and Tschudi in 1952 [4- 6]. 
Since then, m any attem pts have been  m ade to develop extraction m ethods or reactions 
leading to obtaining m orphine [7,8 ].
D rug reactions m ay be extracellular or cellular. The form er involve noncellular con­
stituents (physical effects, chem ical reactions, physicochem ical m echanism s, and m odifi­
cation of the com position of body fluids) [9 ]. In contrast, cellular m echanism s of action 
involve functional constituents of the cell and, m ore frequently, depend on specific b io ­
chem ical reactions. C ellu lar drug reactions apply to physicochem ical and biophysical
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mechanisms, the modification of cell m embrane structure and function, and enzyme inhibi­
tion, as w ell as interactions w ith receptors. Receptors in various locations— for example, on 
the plasma mem brane, in the cytosol, or in the nucleus— and interactions with the receptor 
typically activate or inhibit several sequences of biochem ical events. The existence of recep­
tors has not alw ays been  a m atter of course in  the w orld  of science. Their first exponents 
were John Langley with his theory of receptive substances in cells and Paul Ehrlich and his 
side-chain theory [10,11]. These theories evolved, and a one-drug one-receptor m odel was
proposed, based on the assum ption that a given drug interacts only w ith one receptor.
H itherto, drugs w ith  high target selectivity in the body, designed to affect a single 
biological entity  to avoid adverse side effects, have been  used and searched for [12]. It 
is the concept of a "single m olecule, single target, and single d ru g" that has dom inated 
the pharm aceutical m arket for the last several decades. In som e disease entities, a drug's 
effect on one target is insufficient to achieve the therapeutic effect. Therefore, com bination 
therapy is also used, i.e., the sim ultaneous use of drugs w ith  different b ody targets— for 
instance, in the treatm ent of hypertension [13]. Diseases w ith m ultifactorial pathogenesis 
or not fully understood pathogenesis are often  treated w ith  m ore than one drug, w hich 
increases the risk  of adverse drug reactions. Therefore, m ore and m ore often, as in the 
case of A lzheim er's disease, drugs w ith m ultiple biological targets are chosen in order to 
increase effectiveness, safety, and to facilitate adm inistration— for exam ple, galantam ine, 
caproctam ine, or m em oquin [12] .
Unlike the treatm ent w ith synthetic drugs, phytotherapy is based on herbal medicines, 
and their actions result from  the com bined m echanism s of com pounds contained in the 
raw m aterials or their products [14]. Thus, the effect of a given herbal drug is the result of 
all the synergies or antagonism s betw een its constituents.
Cannabis sativa  L. is one of the m ost ancient p lant species used by hum ans for m any 
purposes. Besides m edicinal use, it also serves as a fiber; food; and is an im portant raw  
m aterial for the production of rope, textiles, and paper. Surprisingly, the first hum an use 
of Cannabis is reported to be 10,000 years ago, a t the end of the Ice A ge [15]. The m ost 
ancient C hinese Pharm acopoea (w ritten  in the first century before the current era), the 
"Sh en  N u ng P en Ts'ao C h in g ", is the first h istorical evidence of the use of Cannabis in 
traditional medicine. It includes all the traditional remedies used and orally bequeathed for 
over two thousand years w hen it was em peror Shen N ung's (2700 years before the current 
era) reign [16]. The Cannabis plant first arrived in Europe w ith Scythians or proto-Scythians 
moving from Central Asia about 3500 years ago [17]. M odern reports on medical marijuana 
date back to the nineteenth century, w hen the Irish doctor W illiam  Brooke O 'Shaughnessy 
perform ed experim ents on  the pharm acological and toxic properties of Cannabis [18,19]. 
H e suggested Indian hem p as a treatm ent for tetanus and other convulsive diseases. In 
1851, for the first tim e, Cannabis w as included in the third edition of the U nited States 
Pharmacopoeia (USP) w ith the use of Cannabis flowers as an analgesic, anticonvulsant, and 
hypnotic [20]. In the second half of the nineteenth century, there w as a significant increase 
in the use of Cannabis in m edicine and research on its phytochem istry and pharmacology. 
A t the beginning of the tw entieth  century, as the recreational use of Cannabis grew, in 
1937, the "M ariju ana Tax A ct" w as introduced, and in  1941, Cannabis w as rem oved from  
the tw elfth  edition of the U.S. Pharm acopeia by the A m erican M edical A ssociation [19]. 
In the 1960s, the use of recreational Cannabis increased throughout the W estern w orld. 
The discovery of the chem ical structure of A9-tetrahydrocannabinol (A9-TH C), which was 
identified by Gaoni and M echoulam , boosted m ultidirectional research on Cannabis [21].
The botanical definition of Cannabis sativa  L. has been  a goal of m any studies due 
to its m orphological and chem ical differentiation. The currently  accepted classification 
distinguishes tw o subspecies— namely, ssp. sativa and ssp. indica. W ithin each of them , 
there are tw o m ain varieties, cultivated and w ild. The m ost im portant from  a m edicinal 
point of view  is C. sativa ssp. sativa var. sativa (so-called C. sativa) and C. sativa ssp. indica var. 
indica (so-called C. indica). C. sativa  ssp. sativa  var. spontanea  (the so-called C. ruderalis) is 
rarely found and much less exploited. The plant develops both male and female specimens.
Dried inflorescences from female plants (Cannabis flos)  are known as marijuana. It contains 
resin, w hich is a source of phytocannabinoids. Purified resin is known as hashish. So-called 
C. indica  is usually  grow n for recreational use, w hereas so-called C. sativa  has recently 
gained m uch attention as a source of m edical m arijuana.
The possibility of interactions between components of various Cannabis products is high 
due to the richness of the compounds. Hitherto, over 100 cannabinoids have been identified 
in the Cannabis sp., and the best know n, fam ous, and responsible for its pharm acological 
activity are the psychoactive A9-tetrahydrocannabinol (THC) and cannabidiol (CBD ) [2 2 ] . 
These cannabinoids are produced in the p lant in acid form  and require decarboxylation, 
w hich  is caused m ainly by  a high tem perature. There are also other cannabinoids in 
the plant, such as cannabigerol (CBG), cannabichrom ene (CBC), cannabidivarin (CBD V), 
and cannabinol (CBN). How ever, the Cannabis sp. com prises not only cannabinoids. The 
presence of over 600 compounds has been reported so far, w ith over 150 different terpenes—  
including m onoterpenes, sesquiterpenes, and, also, di- and triterpenes, as w ell as sugars, 
steroids, fatty acids, non-cannabinoid phenols, flavonoids, phenylpropanoids, alkanes, and 
nitrogenous com pounds [23,24].
The grounds for the conclusion that there are interactions betw een Cannabis p lant 
com ponents is that the Cannabis f lo s  extract has a higher potency than the individual 
isolated cannabinoids, w hich  is called the "entou rage effect" [22 ] . As a result, a m ore 
efficient pharm acological effect can be obtained and a higher therapeutic efficacy am ong 
patients. Individual cannabinoids can in teract synergistically w ith  each other, w hich 
is called the "in tra-entou rage effect". The enhanced therapeutic effect o f cannabinoids 
through other plant secondary metabolites such as terpenoids is called the "inter-entourage 
effect". Terpenoids significantly alter the biological activity of cannabinoids.
Cannabis potency w as initially  defined by the content of TH C. O ver the years, the 
TH C content in products available w orldw ide has elevated [25]. It is w orth  em phasizing 
that the use of products w ith  h igh TH C  contents and low  C BD  contents m ay lead to side 
effects. A case-control study showed that the administration of Cannabis rich in THC might 
be associated w ith  a raised risk of psychosis in patients, m ostly  w hen the C BD  level w as 
relatively low  [26]. The T H C /C B D  ratio is significant in determ ining the potency of the 
Cannabis plant. C BD  does not cause euphoria. Scientists even confirm ed its antipsychotic 
and anxiolytic effect and the reduction of som e side effects of TH C  [27]. U sing C BD  and 
TH C  together is considered to have a m ilder effect. A dditionally, pretreatm ent w ith  
C BD  before the adm inistration of TH C  seem s to be beneficial. In one study, it prevented 
the transient psychotic sym ptom s induced by  TH C  [28]. That is w hy it is so crucial to 
antagonize the psychotic and other side effects of TH C by  using preparations containing 
both THC and CBD.
The vast m ajority of CBD products are readily available to patients worldwide as food 
supplements or additives in food. CBD is administered (with decreasing bioavailability) as: 
v ap in g /sm o k in g ; suppositories (v ag in a l/recta l); su b lin g u al/o ra l m ucosal; nasal sprays; 
capsules; and topicals (lotions, cream s, sham poos, or oils). There are various high-TH C  
products on the m arket: hashish, m arijuana, and oils. Several products are registered for 
m edical purposes. These include m edical m arijuana (Bedrocan®), oil preparations based 
on m arijuana extracts [5 ], highly  purified extracts containing a specific ratio of TH C  and 
C BD  (Sativex®), and synthetic (M arinol® and C esam et®) cannabinoids [29]. In  order to 
differentiate betw een synthetic and natural cannabinoids, the latter are usually referred to 
as phytocannabinoids. Synthetic cannabinoids available on the m arket include Dronabinol 
(M arinol®), w hich  is indicated in adults for the treatm ent of anorexia associated w ith  
w eight loss in  patients w ith  A cquired Im m une D eficiency Syndrom e (AIDS), nausea and 
vom iting associated w ith cancer chemotherapy in patients who have failed to respond well 
to conventional antiem etic treatm ents, and N abilone (C esam et®), w hich  is indicated for 
the treatm ent of nausea and vom iting associated w ith  cancer chem otherapy in  patients 
w ho have failed to respond adequately to conventional antiem etic treatm ents [30]. W hen 
using synthetic analogs in m edicine, the positive interactions betw een the secondary
m etabolites present in  (Cannabis p lants are ignored. The synthetic com pound doers not 
have the opportunity to interact with other compounds that the plant lias to offer and gain 
a sim ilar pharm acological effect as C BD  lias on TH C  (nn increase o f flrn safety of using 
plant-based products). M aybe that is w hy the syntheOic cannabinoid type 1 (CBi) receptor 
antagonist R im onabant (Acom pilia®) (used tee reduce appgtite in o v trw eig h t and obese 
patiente) w as suspended from  the m arket in 200S and w ithdraw n from  Europe in  2009 
due to serious side; effects, such as depression and anxiety disorders and several cases of 
suicide [17,29,31].
2. Endocangnbinoid  System
The endocannabinoid  system  is responsible fo r  the regulation of num erous vital 
Ounotions, including learning, memory, mood, anxiety, drug adgictionl nutritional behavior, 
pain perception, m odulation, and the hm ctions of the cordievascular system. It consists of 
csnnabinoid reteptors, endogenous ligands, secondary m essengers, and endocannabinoid 
degradation pathw ays [ i2 ,33].
This system is still under investigation, but so far, three receptors haue been discovered 
and described: C B1, cannabinoid type 2 (CB2), arid G pnotein-cnupled reoeptor 55 (GPR55). 
They are located extracellularly and intracellularly in the m itochondria, Golgi apparatus, 
a n t  the nucleus [3o], The receptoos that are located on cell membranbs are couplnd w ith the 
G protein. The endocannabm nid system  is regulated by endocannabinoids, w hich are pro­
duced io response to neutal networg actiuity [34S. These ese endogenous ligands produced 
by the hum rn body. The two m ain ones are anandam ide (AEA) and 2-arachidonylglycerol 
(2-AG) [3 t] , Their form ulas are show n in Figure 1. They are dorivatives of arachidonic 
acid, a precursec of num erous endogenous panticles, such as prostaglandins, prostacyclins, 
throm boxanes, and leukotrienes.
A) B)
Figure 1 . Endocannabinoid siructures: (A) anandamide and (B) 2-arachtdonoylglycerol.
These endocannabinoids are produced on dem and from  m em brane precursors and 
phospholipids and are not stored in vesicles lioe o iher neurotransm iitens bu t re ltased  
im m ediately. O nce macie, they return to ihe presynaptic neuoons to attach to receptors 
there. A fter their activation, the influx of potossium  ions into nhe sell incseanes, leading 
to m em brane hyperpolarization. As a e e s ^ E  the likelihood of neurotransm itters being 
released irom  presynoptic n eu ront is reduced. St m akes it im poseible to connect uwith 
other neurotransm itters, such as y-am inobutyric acid (GABA), glutamate, or acetylcholine, 
affecting the central nervous sysoem's -various functions. The stim ulation of cannabinoid 
receptors m ay lead tn a w eakening of their responses, depending on the type of neurons 
they aet on. Afner inducing a  biological response, their reuptake by  endocannabinoid 
m em brane transporters takes plgceo followed by enzym atic degradation [33- 37].
C B1 receptoss m ediate pann m odulation, m em ory processing, m otor function. and 
psychoactivity. They are located m ainly in the brain. They achieve the highest density in 
such structures as the hippocam pus, cerebellum , basal ganglia, cerebral cortex, hypothala­
mus, dorsal vagus nnrve c omplex, sind tpinal cord. Moreover, several receptors ore located 
in the structures responsible for the control of respiratory functions. The C B 1 receptor 
predom inates in  the G A BA  inhibitory interneurons in  the spinal cord 's posterior horn 
over excitatory neurons, w ith  A EA  being its m ajor ligand. These presynaptic receptors 
influence the release of neuropeptides and neurotransm itters and inhibit synaptic con­
duction. Their activation stim ulates potassium  channels, w hich inhibit the presynaptic
stim ulation of neurons and b lock  potentially dependent calcium  channels, w hich reduce 
the release of neurotransm itters. C B 2 receptors are m ainly  associated w ith  the im m une 
system  and are m ostly found in  the spleen, digestive system , peripheral nervous system , 
and testes. A lthough several of them  are located in  the brain, their function in  this organ 
is unclear. K now ing the receptors' exact locations allow s an understanding of how  the 
system  w orks and Cannabis 's  effects on the body. The stim ulation of this receptor does not 
have a psychoactive effect, nor does it affect the circulation. Its main endogenous ligand is 
2-AG. The stimulation of these receptors reduces the release of chemokines and neutrophils 
and the m igration of m acrophages, and w hat is m ore, it has the effect of reducing chronic 
inflam m atory processes and chronic pain. Both C B 1 and C B 2 found on m ast cells are 
involved in the anti-inflam m atory activity of cannabinoids. O n the other hand, activation 
of the C B2 receptor on keratinocytes additionally  increases the release of ß-endorphins. 
The C B 2 receptor stim ulation process leads to the inhibition of adenylate cyclase activity, 
decreased cyclic adenosine m onophosphate (cAMP) production, and increased activity of 
the m itogen-activated kinase. However, the effects on the calcium  and potassium channels 
have not been confirm ed [33,34].
C annabinoid receptor agonists, such as TH C, excite cannabinoid  receptors nonse- 
lectively, producing a nonphysiological response, because hydrolytic enzym es do not 
m etabolize them . Thus, their effect lasts longer and cannot be controlled. The long-term  
effects of TH C  m ay reduce the am ount of the C B 1 receptor and, consequently, w eaken 
the sensitivity  of the endocannabinoid  system . The developed tolerance and decreased 
effect m ay lead to a gradual increase in consum ption frequency or an increase in  the 
dose. H ow ever, it is w orth  noting that this change is reversible ju st four w eeks after 
discontinuation of use. Synthetic cannabinoids are considered "su p erag on ists", as they 
cause long-lasting effects on the endocannabinoid  system , w hich  can cause severe toxic 
effects [34]. Anandamide is broken down by fatty acid amide hydrolase (FAAH) into arachi- 
donic acid  and ethanolam ine. The inhibition of FAAH  increases the levels of A EA  and 
the fatty acid amides oleoyl ethanolam ide and palm itoylethanolam ide. These com pounds 
are no longer endocannabinoids, as they do not act on cannabinoid receptors. Still, they 
have anti-inflam m atory activity and inhibit pain by acting on the transient potential type 1 
vanilloid receptor (TRPV1) and binding to the peroxisom e proliferator-activated receptor 
(PPAR). They can potentiate the effects of AEA by com petitively inhibiting FAAH, w hich 
breaks down anandamide. AEA is a partial agonist of cannabinoid receptors; a full agonist 
of the TRPV1 receptor activates GPR55 and PPAR receptors and inhibits serotonin receptors 
(5-H T3A) and T-type p otent calcium  channels. 2-A rachidonylglycerol is a full agonist of 
the C B 1 and C B2 receptors, and its am ount exceeds the am ount of A EA . It is broken down 
by m onoacylglycerol lipase into arachidonic acid and glycerol [33,35,38]. CBD  can lead to 
an increase in endocannabinoid levels, possibly altering their m etabolism  and regulating 
their reuptake. Therefore, the tw o above-m entioned endocannabinoids can be described 
as secondary m essengers, form ed in  the process of phospholipid  m etabolism , p laying a 
significant role in neurom odulation by  preventing excessive neuronal activation [36,38].
A ccording to m any studies, the m ain functions o f the endocannabinoid  system  in­
clude neurom odulation, stim ulation of the central nervous system  via  C B 1 receptors, 
anti-inflam m atory and im m unom odulating effects obtained by stim ulation of the C B2 re­
ceptor, and neurom odulation by presynaptic inhibition [38]. The endocannabinoid system 
is supposed to m aintain hom eostasis in the body, and disturbances in its functioning m ay 
lead to various pathological states [39]. Some studies have shown an increase in the expres­
sion of cannabinoid receptors in neoplastic cells compared to healthy cells. In vitro studies 
on healthy hum an skin cells have show n that the activation of cannabinoid receptors 
initiates apoptosis in tum or cells and inhibits tum or angiogenesis [40].
3. Chemical Composition
As m entioned earlier, the Cannabis sp. contains num erous phytochem icals like phyto- 
cannabinoids, as w ell as alkanes; n itrogen com pounds; terpenes; and phenols, including 
flavonoids, steroids, fatty acids, and sugars [41].
3.1. Phytocannabinoids
From a phytochemical and pharm acological point of view, phytocannabinoids appear 
to be the most crucial compounds [41]. They are produced m ainly in Cannabis sp., although 
their presence has also been  reported am ong plants belonging to the H elichrysum  and 
Radula  genus [42]. So far, over 100 different phytocannabinoids have been  described in 
Cannabis sariva L., some; of them being the breakdown products of original compounds [43]. 
Phytocannabinoids have 21  carbon atom s or, in the case of carboxylated form s, 22 [42]. 
M ost often, they are tricyclic terpenoid com pounds w ith  a benzopyrene group in their 
structure. Based on the resorcinol side chain, phytocannabinoids have been classified into 
tw o classes: alkyl and ß-aralkyl [43]. ElSohly M. A., on the other hand, grouped cannabi­
noids into 11 chem ical classes, w hich  are preoented in  the diagram  below  (Figure 2) [4n]. 
The otructures of the cannabinoids are show n in Figure 3 .
Two pathw ays are involved in  the production of cannabinoid precursors (Figure 4 ). 
The first is 3he polyketide pathway, w hich  produces olivetolic acid. The second is the 
pathway located in plastids, leading to geranyl diphoophate (GPP). Initially, tha hexaaoate, 
which is a short-chain fatty acid, produces hexanoyl coenzym e A (CoA). The lat4er, in turn, 
by com bining w fth throe m alonyl-C oA  m olecules, gives olivetolic acid, obtained thanks 
to the 4ction of polyketide cyclaso [42]. Then, undar she influence of geranyl transferase, 
cann4bigerolic acid (CBGA) is form ed, w hich is the precursor for m ost cam iabinoids [415]. 
Further transform ations ts  tho proper cannabinoids take place thanks to the appropriate 
oxidocyclases [48]. C BD  and TH C  are synthesized by  the independent cyclizafion of 
cannabfgerolic acid  [4o]. The oxidase reaction to oStain  C BD  m ay be som ploted at this 
stage bu t m ay also atisa during sm oking or due to the acidic environm ent, together w ith 
sm ai( om ounis i f  A9-tetrahydrocannabinol (A9-TH C) and A8-tetrahydrocannabinol (A8- 
THC) [S0]. H ow ever this reaction does not occur naturally in the plant [46].














Figure 3. The structures of cannabinoids: (A) cannabidiol, (B) A9-tetrahydrocannabinol, (C) A8-tetrahydrocannabinol, (D) 
cannabigerol, ( E) cannabichromen, (F) cannabnol, (G) cannabitriol) (FI) cannabielsoin, )I) cannabicyclol, and (J) cannabinodiol.
Figure 4. Diagram of cannabinoid biosynthesis [42]. CoA: coenzyme A.
Q uantitative data indicate that A9-eetrahydrocannabinolic acid (TH C A ), oannabid- 
iolic acid (C BD A ), and cannabnnoic acid  (CBN A ) are the predom inant poim ary phyto- 
connabonoid s of fresh C. sativa L. [42]. O n heating, TH C A  and C BD A  are converted 
into the tw o m ost essential phytocannabinoids produced by C. sativa L.— nam ely, A9- 
tetrahydrocannabinol and cannabidiol [47]. The Cannabis sativa ssp. sativa var. sativa 
(so-called C. sativa) usually  contains m ore C BD  than TH C, w hile the Cannabis sativa ssp. 
indica var. indica (so-called C. indica) usually has m ore TH C  than C BD  [48]. The Cannabis 
sativa ssp. sativa var. spontanea (the so-called C. ruderalis), in turn, is characterized by small 
levels of TH C  [49]. H ow ever, there are m any hybrid  varieties, such as Skunk (75%  sativa 
and 25% indica) [29]. The hybridization process allows for the creation of new strains with 
selected characteristics. After creating hybrids w ith C. ruderalis, w hich has auto-flow ering 
properties (flowers appear according to plant age rather than light conditions), the resulting 
hybrid has the appropriate cannabinoid content and auto-flow ering properties [49]. High 
THC content strains are also obtained [49]. The European Drugs Report 2006-2014 showed 
a significant increase in TH C 's average am ount in resin and dried hem p. A n analysis by 
the US Drug; Enforcement Adm inistration also confirm s this trend. The average THC levels 
have risen from  4  to 12%  over the past tw o decades. A  sim ilar phenom enon has been 
docum ented in A ustralia and the N etherlands. This is likely due to advanced production 
techniques and the desire to elevate THC levels. However, it should be borne in mind that 









The synthesis and accum ulation of phytocannabinoids occur in glandular trichom es 
(epiderm al outgrow ths, consisting of the head and stalk), and their m axim um  concentra­
tion is noted in unfertilized fem ale inflorescences [45]. Besides, they can also be found 
in the leaves and stem , and low  levels of phytocannabinoids have also been  detected  in 
Cannabis seeds. Their contents w ere rem arkably low  in the seed s' interiors and slightly 
higher on the surfaces, possibly  due to contam ination by flow ers or leaves. The concen­
tration of phytocannabinoids depends on the age, variety, type of tissue, environm ental 
conditions during growth, storage conditions, and harvest time [42]. It has been found that 
phytocannabinoids are produced and stored m ainly in  the form  of acids; therefore, their 
concentrations in fresh plants are m uch higher [41,43,45]. Neutral bioactive phytocannabi­
noids are formed by nonenzym atic decarboxylation during drying, storage, and heating as 
a result of the actions of tem perature, light, and oxygen.
Phytocannabinoids are soluble in  lipids and nonpolar organic solvents [43]. Their 
lipophilicity is as follows: CBG > CBC > cannabitriol (CBT) > CBD > cannabielsoin (CBE) > 
THC >  CBDV >  CBN  >  cannabicycline (CBL) [50]. Their lipophilic nature m eans that they 
cross the b lood -brain  barrier and are readily distributed throughout the brain  and nerve 
cell m em branes. Moreover, they m ay gradually be released from the above structures into 
the bloodstream , even over m any w eeks [38].
3.1.1. Cannabidiol-Type Com pounds
C annabidiol w as first isolated in 1940, w hile its structure w as described in the 
1960s [51]. It is the m ain phytocannabinoid  com ponent of hem p. It does not have a psy­
choactive effect; it does not affect the locom otor activity, body tem perature, m em ory, or 
sedation in the user and does not cause abuse but m ay have antipsychotic effects [29,51].
Som e research groups have reported a lack  o f affinity of C BD  for the CB1 and CB2 
cannabinoid receptors. However, a w eak antagonism of these receptors has been confirmed 
in vitro. C BD  also inhibits anandam ide reuptake and can increase anandam ide levels 
according to the inhibition of FAAH. C BD  also is an allosteric m odulator of g and 6 
opioid receptors [51]. In addition to the endocannabinoid system , it shows activity against 
serotonin receptors. Its anti-inflam m atory and im m unosuppressive effects m ay arise from 
the ability  to stim ulate A]_a adenosine receptors [52]. The exact influence of C BD  on the 
receptors is described in Table 1 . C BD  can also reduce TH C 's side effects, giving it a better 
safety profile. In  its presence, at low  concentrations, it can antagonize C B1, preventing 
tachycardia and anxiety and reducing sedation and hunger [53].
Table 1. Postulated effects of cannabidiol (CBD) on the receptors [52,54,55]. Abbrev.: A—adenosine, 
TRPA1—transient receptor potential ankyrin 1, TRPV—transient potential vanilloid receptor, CB— 
cannabinoid, GPR—G protein-coupled receptor, and PPAR—peroxisome proliferator-activated recep­
tor, 5-HT -  serotonin receptor, TRPM -  transient receptor potential melastatin.
Receptor CBD Activity Receptor CBD Activity
CB1 Noncompetitive antagonist, 
negative allosteric modulator
5 -HT1A Agonist
c b 2 Antagonist, inverse agonist 5-HT2A Partial agonist
GPR55 Antagonist 5-HT3A Antagonist
GPR18 Antagonist A 1A Agonist
PPAR-y Agonist channel TRPV1, TRPV2 Agonist
TRPM8 Antagonist TRPA1 Antagonist
a1, a3 glycine receptors Agonist
CBD  has anti-inflam m atory, antioxidant, analgesic, anxiolytic, antitum or activity, 
anticonvulsant, antiem etic, im m unom odulatory, and neuroprotective effects [52,56]. The 
antiepileptic effects of C BD  have been studied in  the treatm ent of som e types of epilepsy. 
The results show ed possible efficacy in the treatm ent of childhood epilepsy. In June 2018, 
the oral solution of Epidiolex® was approved by the US Food and Drug Administration. It 
has been  approved for epileptic seizures in Lennox-G astaut syndrom e (LGS) and D ravet 
syndrom e (DS) from  the age of tw o [29]. The anxiolytic properties of C BD  have been 
show n in both  hum ans and anim als. It is also u nder consideration for use in  cancer, 
inflam m ation, diabetes, and neurodegenerative diseases. It has no harm ful effects. CBD , 
being a com ponent of nabixim ols, has been used in the treatm ent of cancer pain in opioid 
nonresponders [53].
3.1.2. Com pounds of the A9-Tetrahydrocannabinol Type
The A9-tetrahydrocannabinol type includes m any reduced cannabinol form s that 
differ from each other in a stereochemical configuration or double-bond position. The most 
im portant and best-know n com pound in this group is, how ever, A9-TH C , w hich  is the 
main com ponent of Cannabis [43,46]. Its structure is shown in Figure 3 . The first isolation of 
A9-THC took place in 1942 [57]. O nly over tw enty years later, Messrs. Raphael M echoulam 
and Yechiel G aoni described its structure based on a Lebanese hashish sam ple using 
m agnetic resonance spectroscopy [21]. The determ ined localization of the double bond 
had never been  considered in studies before. Santavy defined the absolute configuration 
of the narcotic com ponents, evidencing the relationship betw een the structure of A9-THC, 
A8-TH C, and CBD  [58,59] . The natural form  of A9-TH C in plants is a m ixture of its acidic 
form s— TH C A -A  and TH CA -B. They occur in  plants in various concentrations, their 
decarboxylation takes place at different tem peratures, and additionally, they have different 
crystalline forms. As a pure substance, A9-THC is unstable. It exists in an amorphous gum 
form and tends to brown. It show s greater stability in the unprocessed plant product, and 
it m ight be stored in a chilled m ethanol solution. The degradation rate of A9-TH C  in the 
p lant product k ep t a t room  tem perature is about 5% , w hile, for the pure substance, the 
value is around 10%. O ne of its degradation products is cannabinol [46].
As a partial agonist of CB1 and CB2 receptors, A9-THC adopts an agonist or antagonist 
profile, depending on the receptor expression, cell type, and the presence of full agonists 
or endocannabinoids. It is the com pound responsible for the pharm acological effects of 
Cannabis. A9-TH C also im pacts other receptors. It is a G PR 55 and G PR 18 receptor agonist. 
It has anticancer activity, and it causes vascular relaxation, according to PPA R-y receptor 
agonism . M oreover, its analgesic properties m ight result from  the influence on glycine 
receptors. Som e studies have proven the agonism  of A9-THC against TRPV2, TRPV3, and 
TR PV 4 channels, bu t no response to TRPV1 w as observed [52]. The detailed activity  of 
A9-THC on individual receptors is included in Table 2 .
Table 2. The effect of A9-tetrahydrocannabinol (A9-THC) on the receptors [52].
Receptor A9-THC Activity Receptor A9-THC Activity
CBj Partial agonist opioid receptors Allosteric modulator
c b 2 Partial agonist PPAR-y Agonist
GPR55 Agonist TRPV2, TRPV3, TRPV4 Agonist
GPR18 Agonist TRPA1 Agonist
5-HT3A Antagonist TRPM8 Antagonist
Even in early studies, the narcotic properties of Cannabis sp. were linked to the reduced 
form of cannabinol— the first structurally known cannabinoid [46]. A9-tetrahydrocannabinol 
is know n for the ability to induce psychotropic effects. Its chronic adm inistration causes 
various central and peripheral effects, confirm ed in  hum ans and anim al m odels [41]. It 
exhibits anti-inflam m atory, antiem etic, and neuroprotective properties, and it seem s to be 
effective in  the fight against chronic and neuropathic pain  [60]. TH C  is also responsible
for the addictive effect of Cannabis [ 29] . However, its acidic counterpart has antibiotic and 
neuroprotective potential [41,43]. Interestingly, com pared to other cannabinoids, A9-THC 
has low acute toxicity at the m edian lethal dose (LD50) level of 100 m g /k g  [46].
3.1.3. Com pounds of the A8-Tetrahydrocannabinol Type
A8-tetrahydrocannabinol m ight be form ed according to CBD  cyclization or a A9-THC 
molecule double-bond location change [61]. The CBD cyclization process varies depending 
on the reaction conditions. The A9 isom er is formed under m ildly acidic conditions, w hile 
the A8 isom er is form ed at a higher acidity and tem perature. A8-TH C is m ore stable than 
A9-THC, and it is easier to obtain, which may stimulate the isom erization towards A8-THC. 
A8-TH C  show s a sim ilar im pact on A9-TH C  as the receptors bu t w ith  a slightly low er 
potency [46]. The structure of A8-THC is show n in Figure 3 .
3.1.4. Com pounds of the Cannabigerol Type
The cannabigerol-type cannabinoids constitute the m ost structurally  diverse class 
of phytocannabinoids. They can have various m odifications of the isoprenyl group, the 
resorcinol core, and different substituents [46] . By 2005, eight com pounds of this type had 
been reported, w hile nine new ones were added recently [62]. In this class of cannabinoids, 
CBG and cannabigerovarin (CBGV) are of the m ost significant im portance [46].
The first com pound isolated from  Cannabis resin w as cannabigerol [62]. The plant is 
rich in CBG, w hich has no psychoactive effects [43,52]. Its acid form, i.e., CBGA, may serve 
as a potential precursor for other cannabinoids [52]. Recently, a Cannabis sativa hybrid was 
obtained rich  in  this com ponent [46]. The structure of cannabigerol in an acid or alkali 
environm ent is not stable [46]. Its structure is show n in Figure 3 .
CBG inhibits anandam ide reuptake, and the affinity for C B1 and C B2 receptors is low. 
It is a w eak agonist of TRPV1 and TRPV2, a strong agonist of TRPA1, and a potent antag­
onist of TR PM 8 . Its non-cannabinoid  activ ity  is based  on the ability to block the 5 -H T 1A 
receptor and activate the a 2 adrenergic receptor. CBG stim ulates the a 2 receptor; inhibits 
catecholam ine release; and causes sedation, analgesia, and m uscle relaxation [46] . Studies 
have dem onstrated the possible neuroprotective effects of cannabigerol in H untington 's 
disease [63]. M oreover, it m ight be a prom ising com pound in the treatm ent of glaucom a, 
prostate cancer, and inflam m atory bow el diseases. H ow ever, these applications require 
additional research [64] . O ther sources report its antibiotic, antifungal, analgesic, antioxi­
dant, and anti-inflammatory effects [65]. Unfortunately, the knowledge about cannabigerol, 
despite several studies conducted so far, rem ains lim ited for the tim e being [66 ] .
3.1.5. Com pounds of the Cannabichrom e Type
C laussen and, independently, G aoni and M echoulam  revealed a cannabichrom ene 
structure in 1966 [67,68]. Cannabis sativa is rich in CBC. Its increased content in the plant is 
often associated w ith  h igh TH C  levels, w hich  m ay be related to a com m on biosynthetic 
pathw ay [52]. The CBC  structure is presented in Figure 3 . A  high concentration of the 
acid form  of C BC— cannabichrom ene acid— w as found in young Cannabis plants, and its 
decrease progressed w ith  the m aturation of the p lant [42]. It is a racem ic com pound that 
glows blue fluorescence under UV light and shows considerable stability [43,46]. It inhibits 
anandamide uptake. Cannabichromene is an agonist of the TRPA1 channels; it m ight block 
TPRM 8 and activate the TRPV3 and TRPV4 channels. Its affinity for cannabinoid receptors 
is low, it is a selective C B2 receptor agonist, and it can also recruit CB2 receptor regulatory 
m echanism s [52,69] . The antibiotic, antifungal, anti-inflammatory, and analgesic effects of 
cannabichrom ene are noticed [69].
3.1.6. Com pounds of the C annabinol Type
C annabinol w as the first phytocannabinoid isolated from  Cannabis  sp. Then, W ood, 
Spivey, and Easterfield  w ere able to extract C BN  from  a sam ple of Cannabis  orig inat­
ing in  India in  1896 [70]. In  1940, A dam s described its structure, and for the next tw o
decades, it w as the only com pound described structurally in this class [71]. It is believed 
that derivatives, analogs, and C BN  itself derive from  TH C -type com p ou nd s' oxidative 
aromatization reaction. The conversion process from THC to CBN can occur spontaneously 
in both Cannabis extracts and raw plant m aterials. C BN  is a stable com pound. It has been 
used as a m arker for identifying Cannabis in various archaeological finds [46]. It has a low 
affinity for the C B1 and CB2 cannabinoid receptors, but it is slightly higher for C B2 [43]. It 
is also an antagonist of the TPR M 8  channels and a p otent agonist of TRPA1. It has been 
described as a w eak psychoactive com pound [52]. Studies have indicated the antibiotic, 
sedative, anti-inflammatory, and anticonvulsant effects of C BN  [65]. Its structure is shown 
in Figure 3 .
3.1.7. Com pounds of the of C annabitriol Type
C annabitriol w as first isolated in 1966 by  O bata and Ishikaw a [72]. It w as obtained 
by the oxidation of A9-TH C catalyzed by  antibodies. However, its chem ical structure w as 
know n ten years later. The content of C BT in the p lant is low  [43]. Its pharm acological 
properties are not yet known [72]. Its structure is show n in Figure 3 .
3.1.8. Com pounds of the C annabielsoin Type
The plant produces cannabielsoin in small amounts. It is found only in some varieties 
of Cannabis sativa  L. It is a m etabolite of C BD , w hich  is obtained after photooxidation or 
biotransform ation  w ith  tissue culture [43,52]. E lsa Boyanova w as the first to isolate the 
first com pound from  this group in the laboratories of R aphael M echoulam  [46,73]. CBE 
is the m ain product in the cannabidiol pyrolysis, w hich  is w hy it is likely to be found in 
the sm oke generated during sm oking Cannabis [46] . Its effect on cannabinoid receptors is 
unknow n yet, but it is proven that cytochrom e P450 1A1 (CYP1A1) is the m olecular target 
of CBE [52,74]. The CBE pattern is show n in Figure 3 .
3.1.9. Com pounds of the Cannabicyclol Type
C annabicycline w as initially nam ed TH C-III, according to its structural sim ilarity to 
TH C  [46]. C BL is form ed by heating cannabichrom ene [46]. This com pound does not 
induce narcotic effects [46]. It has little affinity for the C B 1 and C B 2 receptors [43]. CBL 
inhibits acetylcholinesterase (AChE) less than THC or C BN  but more than CBD or CBG; it 
is less lipophilic than m ost cannabinoids [50]. The CBL structure is show n in Figure 3 .
3.1.10. Com pounds of the Cannabinodiol Type
Cannabinodiol (CBND) w as first described in 1977 [75]. It is an analog of cannabidiol 
obtained by its photochemical conversion; its content in the plant is low [52]. Its pharm aco­
logical properties have not been  described yet. H ow ever, it is know n that C BN D  show s 
psychoactive effects [52]. The CBN D  structure is presented in Figure 3 .
3.2. Terpenes
A nother biologically  active group of com pounds found in Cannabis sativa  L. are 
terpenes. There are over 150 d ifferent terpenes in Cannabis. M ost of them  are n ot unique 
for Cannabis sp.; they occur in many plants from various families. Terpenes are synthesized 
like cannabinoids in  trichom es. The m ean contents of terpenes in C. sativa  L. vary  from  
0 .5 -3 .5% ; they also can be identified in  sm oke and fum es generated during sm oking or 
vaporization [60] . There seem s to be a close relationship betw een the p lant's cannabinoid 
and terpene contents [45]. Being the main secondary metabolites besides cannabinoids, they 
could be used as chemotaxonom ic markers [42], but they were not taken into account in the 
classification system s used so far [76] . Terpenes are classified according to the num ber of 
five-carbon fragments known as isoprene units. Those found in Cannabis include ten-carbon 
m onoterpenes, fifteen-carbon sesquiterpenes, and thirty-carbon triterpenes (Figure 5 ).
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Figure 5. The structures of: (A)—monoterpenes (A 1— a-pinene, J2— 2—limonene, A3—terpinolene, A4— 
a-myrcene, and A5—linalool); (B)—sesquiterpenes (B i— ß-caryophyllene and B2— a-humulene); 
and (C)—triterpenes (Ci —friedelin and C2— ß-amyrin).
The m ono- an d sesquiterpenes shown in Figure 5 have b een found in parts of the plant, 
such as the leaves, roots, and flow ers. A m ong m onoterpenes, w e can distinguish the: pre­
dominant constituents of the volatile terpene fraction: D-limonene, linalool, ß-m yrcene, ter­
pinolene, and a -  and ß-pinene. Sesquiterpenes (Figure 5 ), including ß-caryophyllene and 
a-hum ulene, are found in significant am ounts in Cannabis extracts. Triterpenes (Figure 5 ) 
are found in Cannabis roots. These are friedelin and epifriedelanol, as w ell as ß-am yrin in 
Cannabis fibers. C ycloartenol, dam m aradienol, and ß-am yrin w ere detected in hem pseed 
oil [42].
There are tw o m ain biosynthetic pathw ays for p lant-derived terpenes, as show n in 
Figure 6 . The first is the plastidic m ethylerythritol phosphate (M EP) pathw ay responsible 
for the production of m onoterpenes, diterpenes, and tetraterpenes. The second, the cy­
tosolic m evalonic acid (MVA) pathway, is involved in the synthesis of sesquiterpenes and 
triterpenes. The initial substrates of the pathw ays are pyruvate and acetyl-CoA . They are 
converted to isopentenyl diphosphate (IPP) and then isom erized to dim ethylallyl diphos­
phate (D M A PP). W ithin the M EP pathway, the condensation of IPP and D M A PP occurs 
and the form ation of GPP, w hich is a precursor to m onoterpenes. In  the MVA pathway, 
tw o IP P  m olecules and one D M A PP are com bined, resulting in the form ation of farnesyl 
diphosphate (FPP), w hich is sesquiterpenes' and triterpenes' precursor [42].
Figure 6. Diagram of the biosynthesis of monoterpenes (A ), sesquiterpenes, and triterpenes (B) [42]. MEP: methylerythritol 
phosphate, IPP: isopentenyl diphosphate, DMAPP: dimethylallyl diphosphate, GPP: ge ranyl diphosphate, MVA: mevalonic 
acid, and FPP: farnesyl diphosphate.
Studies have been  conducted com paring the terpene profile of Cannabis sativa ssp. 
indica var. indica (so-called (C. indica) and Cannabis ssp. sativa var. sativa (so-called C. 
sativa), in order to distinguish them  accordtng to their terpene profiles. In  plants o f the 
form er variety, h igher am ounts of ß-m yrcene and lim onene or a-p inene w ere found. O n 
the other hand, fhe terpene p rofiles of the Cannabis hativa ssp. sativa var. sativa (called C. 
sativa) proved to be m ore eom plex. Som e planls w ere m ore abundant in a-terpinolene or 
a-pinene, w hile, in others, ß-m yrcene, accom panied by a-terpino lene or trans-ß-oeim ene, 
w as predom inant [77].
The different terpene profiles; have an impect on the odor and the taste of Cannabis [60,76]. 
The sm ell of Cannabis sativa ssp. sativa var. saSiva (ro-called C. sativa) is described as herbal 
or sw eet, w hile the arom a of Caenabis sativa ssp. indica var. indica (so-called C. indicn) 
is defined as irritating and sm elly [48] . A ccording to the fact that terpene com pounds 
are the source o f the p lant's characteristic cm ell, som e of them , such as ß-caryophyllene 
and caryophyllene oxide, are used to train  dogs to enable the detection of m arijuana or 
hashish [41].
Som e terpenes are found only, in the fresh plant due to their volatile nature— lor 
eeam ple, a-p inene and lim onene [41]. The environm ental conditions and piant m aturify 
influence the am ount of terpenes produced by  the plant and its dirtribution.
Terpenes found in Cannabis have a w ide variety of biological properties [76]. Nerolidol, 
constituting 0.09% of Cannabis terpenes, is active against m alaria and leishm aniasis [42]. D- 
lim onene has cytotoxic in vitro, im m unostim ulatory, and anxiolytic properties. ß-am yrin 
has been  recognized as a com pound w ith  analgesic, anti-inflam m atory, and anxiolytic 
properties. a-Pinene shows an im provem ent in m em ory capacity as it acts antagonistically 
to m em ory deficits caused by A9-tetrahydrocannabinol, inhibiting  acetylcholinesterase. 
Cannabis contains linalool, also present in Lavandula angustifolia, show ing anxiolytic, anal­
gesic, anticonvulsant, and anti-inflam m atory effects. ß-C aryophyllene, also found in 
copaiba balm  and b lack  pepper, has anti-inflam m atory and cytoprotective properties 
for stom ach cells. It also binds to the C B2 receptor. Pentacyclic triterpenes, such as ß- 
amyrin and cycloartenol, show antibacterial, antifungal, antitumor, and anti-inflam m atory 
properties [42].
Triterpenes m ight play an essential role in Cannabis biological activity and change the 
properties of the cannabinoids [60]. Products containing cannabinoids, such as Sativex®, 
Cannador®, and Bedrocan®, m ay contain terpenes as support. As m entioned above, due 
to the "entourage effect" hypothesis, cannabinoids are m ore pharm acologically  effective 
w ith  terpenes than them selves [78]. Terpenes m ay alter the pharm acokinetics of TH C 
by increasing the perm eability  o f the b loo d -b ra in  barrier [79]. M oreover, they m ay also
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affect their affinity to CB1 receptors and influence the analgesic and psychotic effects 
of cannabinoids related to their interaction w ith  neurotransm itter receptors [80] . Thus, 
the effects of Cannabis are likely  to be the sum  of the interactions betw een cannabinoids, 
terpenoids, and flavonoids [79]. How ever, no  clinical trials confirm ing these effects have 
been conducted [78]. Com binations of cannabinoids and terpenes are already used to treat 
certain conditions. Som e of them  are presented in Table 3 .
Table 3. Examples of the use of combinations of cannabinoids with terpenes [64]. CBG: cannabigerol.
Cannabinoids Terpenes Use
CBD limonene, linalool, pinene acne treatments
CBG pinene antiseptics
CBD limonene, linalool anxiety disorders
Extract C BD /TH C  1:1 caryophyllene, linalool, myrcene sleep disorders
3.3. Phenolic Compounds
Phenolics, including flavonoids, lignans, and stilbenes, are yet another group of com ­
pounds found in Cannabis [42]. Phenolic com pounds are synthesized from phenylalanine 
through the cytoplasmic phenylpropanoid pathway. This precursor is phenylalanine, w hich 
can be transformed into esters, lignans, lignans, flavonoids, stilbenes, and coumarins. These 
com pounds are form ed m ostly  from  tyram ine and esters of coenzym e A w ith  coum aric 
acid (p-coum aroyl-C oA ), caffeic acid (caffeoyl-C oA ), and coniferic acid (coniferyl-C oA ). 
The course of the synthesis of flavonoids is show n in the diagram  (Figure 7) [42],
Figure 7. Diagram of the biosynthesis of phenolic compounds [42].
Twenty-six flavonoids, w hich m ainly represent flavonols an d flavones, w e re isolated 
from (Cannabis sp., including; apigenin, luteolin, kaempferol, vitexin, isovitexin, orientin, and 
quercetin [80,81]. There is a considerable variation in the content o f flavonoids betw een 
different varieties of C. satfva L ., as w ell as betw een the individual parts of thin plant. 
Their presence has been  confirm ed in  flow ers, tw igs, leaves, and pollen. M ethylated 
isoprenoid flavonns, cannflavin A and cannflavin Bf first isolated in 1980 by  Crnm bie and 
Jam ieson w ere a h o  reported (Figure 8 ) [82], T h eb io lo g ica l antivity of cannflavins seem s 
to be connected w ith  their structure: a prenyl side chain— a geranyl (C f 0— cannflavin A) 
or a d im ethylallyl (C5— cannflavin  B) group), w hich  is atiached to the six position of the 
flavone A -ring— and m odification at the 3' flavone B-ring position w ith a m ethoxy grnup, 
w hich  elevates the lipophilicity  and results in a higher perm eability  through biological 










w as isolated [81]. It seem s that the germ ination process elevates the production of the 
m entioned cannflavins [80].
Figure 8 . The structures oi cannflavins: (A)—cannflavin A and (B)—Cannflavin B.
C ann abis  sp. flav on oid s have an tib acteria l, ante-inflam m atory, an tip ro lifera tiv e , 
and n eu ro p ro tectiv e  p rop erties. F lavonoid e can  a ffe ct the p h arm aco k in etics of 
A9-tetrahydrocannabinol [80]. Besides, apigenin  leas estrogen and anxiolytic propereies. 
C annflavins A and B, due to the inhibition of 5-lipoxygenase and prosfaglandin Ef, show 
anti-inflam m atory eifects [42], Moreover, cannflavin B exhibits antimicrobial and antileish- 
m anial activity [80].
Two groups of lig n res  w ere detected in C. sativa  L.: lignanam ides and phenolic 
am ides. They occur in the roots, fruits, and seeds of the p lant [81]. The lignanam ides 
found in Cannabis include cannabisins and grossamide. For the first time, cannabisin A was 
detected from Cannabis sativa in 1991 [8 6 ] . Later, more and more cannabisins w ere identified. 
Cannabisins M , N, and O  were identified quite recently, in 2015 [87] . They have antioxidant, 
anti-inflam m atory, and neuroprotective properties [87,88]. C annabisin  D  is present in 
Cannabis leaves, and its am ount increases strongly w ith exposure to U V light. Significant 
levels of lignans such as syringaresinol, pinoresinol, lariciresinol, and secoisolariciresinol 
were determined in the hydrophilic extract obtained from Cannabis seeds. However, it was 
found that the total am ount of lignans in Cannabis seeds is about 20 tim es low er than in 
flax seeds and is only 32 m g per 100 g of dry w eight [89]. M oreover, the content in  the 
seed shell is only  1%  of the lignans content in  the w hole seed. Lignans have antiviral, 
antioxidant, antidiabetic, and anticancer properties and can be used in the treatm ent of 
obesity [90]. Additionally, som e of the lignans m entioned earlier can transform , under the 
influence of anaerobic intestinal microflora, into enterolignans, which are the precursors of 
estrogens for m am m als. D ue to their sim ilar structure, enterolignans and estrogens m ay 
potentially  be used in  the future in  the treatm ent of certain horm one-dependent cancers. 
In vitro studies have described the cytoprotective and anti-inflam m atory properties of the 
lignanam ides [42].
N ineteen stilbenes containing phenanthrene, bibenzyl, and spiran rings in their struc­
tures w ere isolated from Cannabis plants. Am ong them  w ere cannabistilbene I, IIa, and IIb 
and dihydroresveratrol. Under the influence of UV light, the num ber of dibenzyl stilbenes 
in Cannabis leaves w as elevated [42]. C anniprene, belonging to the d ihydrostilbenoids, 
inhibits the activity  of proinflam m atory eicosanoids [80]. Tiantian G uo et al. isolated the 
follow ing stilbenoids from  Cannabis sativa  L. leaves.: a ,a /-dihydro-3,4/,5-trihydroxy-4,5;- 
d iisopentenylstilbene, com bretastatin B-2, a ,a ! -dihydro-3/,4 ,5/-trihydroxy-4/-m ethoxy-3- 
isopentenylstilbene, a ,a ! -dihydro-3,4/,5-trihydroxy-4-m ethoxy-2,6-diisopentenylstilbene, 
and a , a ' -dihydro-3/,4 ,5/-trihydroxy-4/-m ethoxy-2/,3-d iisopentenylstilbene and cannabi­
noids [91]. The isolated compounds were cytotoxic to hum an cancer cells by inhibiting their 
proliferation and inducing cell death. M oreover, stilbenoids can increase the cholesterol 
transfer to hepatocytes by  im proving the protein expression and acid bile synthesis.
3.4. Fatty Aids
The Cannabis  sp. contains also fatty acids that can be found m ainly in  hem pseeds. 
H em pseeds also include proteins (20-25% ), carbohydrates (20-30% ), oil (25-35% ), and 
insoluble fiber (10-15% ) and m inerals [92,93]. The fatty acid com position of Cannabis sativa 
seeds w as investigated in the last century. The presence of both saturated and unsaturated 
acids w as determined [94]. The following acids were identified: arachidic, linoleic, behenic, 
eicosadienoic, lignoceric, palm itic, eicosenoic, linolenic, sativic, stearic, m yristic, oleic, 
palm itoleic, and cisvaccenic from  different Cannabis seed preparations [94] . The different 
varieties of Cannabis m ay differ in both the qualitative and quantitative com positions of 
fatty  acids. H ow ever, there is no correlation betw een the seeds' fatty  acid com position 
and their geographical origin [94]. As the seeds m ature, the com position of the fatty acids 
changes— the m ore m ature the seed, the higher the percentage of unsaturated fatty acids 
and the lower the percentage of saturated [94]. Unsaturated fatty acids are essential for cell 
structure. They m odulate cell m em brane fluidity, structural m aintenance, and have a role 
in cell signaling [95]. Fatty  acids are precursors for the biosynthesis of m any functional 
m etabolites [95]. Fatty acids also have antioxidant properties and regulate the nervous sys­
tem , blood pressure, hem atic clotting, inflam m atory processes, and glucose tolerance [96]. 
Cannabis seeds have a desirable ratio of omega-6 and om ega-3 polyunsaturated fatty acids 
considered optim al for hum an nutrition. The consum ption of the fatty  acids in the ratio 
correlates w ith the reduced occurrence of degenerative cardiovascular disease, depression, 
and neurodegenerative diseases like A lzheim er's disease [97,98].
4. Pharmacological Application
The effectiveness of e x tra ctso r  drugs from  Cannabis sp. or synthetic cannabinoids 
in diseases (Figure 9 .) has been  show n below. D ata indicating the clinical effectiveness 
of cannabinoid com pounds in  such a w ide array of dssease units is an argum ent for their 
m ultitarget action. The ability  to antagonize or agonize CI31 and C B2 receptors results 
in the stim ulation nr inhibition of the endocannabinoid  system , both  in the peripheral 
tinsues and in the centrol nervous system . As indicated below, Cannabis sp. extracts have 
significant therapeutic potential. Still, due to ehe need to continue eurflinr clintcal trihls, 
they should be useo as one of the last therapeutic procedures.
Figure 9. Pharmacological applications of extracts or drugs from Cannabis sp. or synthetic cannabinoids in diseases. 
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Epilepsy is believed to be the m ost common noninfectious neurological disease. M ore­
over, one-third of patients suffer from  seizures resistant to standard antiepileptic drugs. 
A ntiepileptic drugs have been  used for over 160 years. They prevent seizures, bu t there 
is no evidence that they have disease-m odifying properties. They affect the m echanism s 
causing the brain 's excitability. A ntiepileptic drugs disrupt the creation and spread of 
ep ileptic hyperactivity. These drugs act on the follow ing m echanism s: (i) m odulation 
of voltage-dependent sodium  channels (carbam azepine and phenytoin), calcium  chan­
nels (ethosuxim ide), and potassium  channels (retigabine and ezogabine); (ii) enhance­
m ent o f inhibited G A BA  transm ission (benzodiazepines, tiagabine, and vigabatrin); (iii) 
w eakening of the stim ulant glutam ate transm ission (peram panel); and (iv) presynaptic 
modification of neurotransm itter release (levetiracetam , brivaracetam , gabapentin, and pre- 
gabalin) [99]. Drugs introduced before 1989 are called "first-generation" drugs, and those 
introduced later are named "second-generation" drugs. M edicines that have been recently 
approved (brivaracetam , eslicarbazepine acetate, lacosamide, perampanel, rufinamide, and 
stiripentol) that are im provem ents to classic drugs or rely on novel m echanism s are called 
"third-generation" drugs [100]. Since 2018, the last group has also included CBD.
D rug-resistant ep ilepsy is d iagnosed w hen  sym ptom  control cannot be achieved 
despite the use of at least tw o different antiepileptic drugs in an appropriate dose [101 ] . 
Epilepsy w ith the greatest resistance to treatm ent includes LGS, DS, fever-related epilepsy 
syndrom e, and epilepsy in tuberous sclerosis syndrom e (TSC) [102]. The patient's quality 
of life and cognitive and psychosocial problem s significantly deteriorate.
D ue to the occurrence of drug-resistant ep ilepsy and severe side effects associated 
w ith  the use of traditional antiepileptic drugs, preparations w ith  higher safety and effec­
tiveness are being sought. The antiepileptic use of Cannabis dates back to ancient tim es. It 
is generally  accepted that Cannabis  benefits in anticonvulsant therapy are linked to CBD. 
H ow ever, the m echanism  of C BD  action in  the treatm ent of ep ilepsy is not fully under­
stood. The orphan G -protein coupled receptor, G PR 55 antagonism , is m entioned as the 
m echanism . R ecent studies have show n that C BD  significantly reduces the num ber of 
seizures. Moreover, it seems that only mild side effects occur. Am ong these, increased liver 
enzym es levels are im proved w ith a continuity of therapy or by dose reduction. However, 
it should be em phasized that C BD  is m ost often used in studies with standard antiepileptic 
therapy, so it is difficult to assess w hether it has antiepileptic effects or only enhances the 
effects of traditional drugs [103]. The FDA approved a 99% CBD extract called Epidiolex in 
2018 for the treatm ent of seizures associated w ith LGS, DS, or TSC  in patients one years of 
age and older [104].
In recent years, there has been an increased interest in the use of Cannabis as part of the 
treatm ent of childhood epilepsy, among others, due to num erous media reports on children 
w hose sym ptom s im proved w ith  C annabis . M any parents of children struggling w ith  
drug-resistant epilepsy turn to alternative therapeutic m easures, som etim es w ith doctors' 
help and sometimes on their own [101]. A lot of attention was focused on a Colorado family 
w ho w as looking for alternative treatm ents for a girl suffering from  D S, C harlotte Figi. 
H er supportive treatm ent included a CBD-rich Cannabis strain that w as later named "W eb 
C harlo tte." A fter three m onths of using it, the num ber of seizures dropped from  300 per 
w eek  to 30 per m onth. H ow ever, after 20  m onths o f treatm ent, the m onthly num ber of 
attacks w as about three, and the girl started talking and w alking [104].
The effectiveness of CBD against the drug-resistant seizures that occur in DS has been 
studied. DS is a type of childhood epilepsy w ith a low  efficacy of traditional antiepileptic 
drugs and a h igh m ortality rate. A  random ized, double-blind clinical trial w ith a placebo 
control w as performed. The groups were random ly selected among 120 children and young 
adults, and the patients w ere subjected to standard antiepileptic treatm ent. Participants 
w ere adm inistered 2 0 -m g /k g  body w eight C BD  daily as an oral solution or placebo. The 
results w ere reported after 14 w eeks of treatm ent and are presented in Table 4 [105]. CBD
is more effective than a placebo in reducing epileptic seizures in patients suffering from DS. 
A t the sam e tim e, such therapy carries a greater risk of side effects [105].
Table 4. Results of the efficacy of CBD in the treatment of epileptic seizures in Dravet's syndrome in children [105].
Test Group Control Group
Number of patients 61 59
Applied treatment 20 mg/kg body weight of cannabidiol daily Placebo
Number of seizures per month after four weeks 
of standard treatment 12.4 14.9
Number of seizures after 14 weeks of 
study treatment 5.9 14.1
The proportion of patients in whom the number 
of seizures decreased by at least 50% 43% 27%
Percentage of patients who were completely 
seizure-free 5% 0%
In a phase 3 clinical trial, 225 LGS patients aged 2-55  years w ith two or more seizures 
per w eek w ere adm inistered CBD oral solution— 10 m g /k g  body w eight per day or twice, 
in addition to a conventional antiepileptic regimen to patients in the test group and placebo 
for 14 w eeks. The m edian percent reduction in seizure frequency from  the baseline w as 
37.2%  in  the C BD  10 m g /k g /d a y  group, 41.9%  in  the C BD  20 m g /k g /d a y  group, and 
17.2% in the placebo group [106]. The reduction in seizure frequency w as dose-related.
A m ong 171 patients aged 2 -5 5  years diagnosed w ith  LG S, w hose seizure frequency 
over four w eeks w as at least two per w eek and w ho did not respond to treatm ent w ith at 
least two antiepileptic drugs (the m ost com m on were lam otrigine, valproate, and clobazam), 
86  patients received C BD  at a dose of 20 m g /k g /d a y  for 14 w eeks; the rest obtained a 
placebo [107]. After 14 w eeks of treatm ent, the monthly seizure frequency had decreased by 
a m edian of 43.9% from the baseline in the CBD group. A 50% or more reduction in seizure 
frequency was reported in 44% of patients in the CBD group and 24%  of the placebo group. 
Serious adverse events (pneum onia, viral infection, increase in alanine am inotransferase, 
increase in aspartate am inotransferase, and increase in y-glutam yltransferase) occurred in 
23.26%  of patients in  the C BD -treated group and in  4.71%  in  the placebo group. Serious 
treatm ent-em ergent (increased levels of alanine am inotransferase, aspartate am inotrans­
ferase, and Y-glutam yltransferase) occurred in  four patients in  the C BD  group. Instead, 
the m ost com m on not serious adverse events (vom iting, diarrhea, loss o f appetite, and 
somnolence) occurred in 61.63% of the CBD group and 50.59% of the patients in the placebo 
group. The study show ed m any side effects in  patients using C BD , bu t in this group, the 
reduction in seizure frequency w as greater than in the placebo group.
4.2. Sclerosis M ultiplex
M ultiple sclerosis is the m ost com m on inflam m atory dem yelinating disease o f the 
central nervous system . It arises as a result of an autoim m une response directed against 
myelin, which, in consequence, leads to worsening neurodegeneration and disability [108]. 
Com m on sym ptom s of m ultiple sclerosis include vision problems, pain, m uscle weakness, 
balance problem s, and paralysis [109]. In addition, patients w ho suffer from  spasticity, 
which is defined as the activation of m uscles w ithout the patient's will, are under increased 
risk of com plications and are subject to pain and problem s w ith falling asleep [110]. These 
sym ptom s are caused by  progressive abnorm al neuronal transm ission. The d isease is 
in itially  characterized by  long asym ptom atic periods abruptly  interrupted by  relapses, 
usually  lasting several days or w eeks [109]. The beginning of m odern treatm ent of m ul­
tiple sclerosis can be associated w ith  the introduction of interferon beta and glatiram er 
acetate in the treatm ent of m ultiple sclerosis w ith  relapsing rem ission [111] . Then, m ono-
clonal antibodies were introduced, such as natalizum ab, and, later, also alem tuzum ab and 
ocrelizum ab. O ral m edicines such as fingolim od, teriflunom ide, dim ethyl fum arate, and 
cladribine have also been developed.
New therapeutic options are still being sought, especially for continuously progressive 
forms of the disease. Currently, the available therapies m ay delay disease progression and 
reduce the num ber of attacks but do not im prove the patients' quality of life [56,108].
N um erous clinical and preclinical studies give hope that cannabinoids derived from 
Cannabis sativa  L. can be used to control chronic pain and spasticity. Preclinical studies 
have also demonstrated the potential use of endocannabinoids' neuroprotective properties 
and partial inhibition of disease progression [108]. N abixim ols, TH C, and oral Cannabis 
extract are believed to be helpful in  the treatm ent of spasticity. Sativex® is currently  the 
only pharm aceutical product approved for this indication. H ow ever, Sativex® is not a 
first-line treatm ent. It is indicated for the relief of m oderate-to-severe spasticity symptoms 
in adult sclerosis m ultiplex (SM) patients who are unresponsive to other spasticity-relieving 
m edicinal products and show a clinically significant im provem ent in spasticity sym ptom s 
in the initial stage of therapy. M edical marijuana reduces the pain and spasticity in SM  but 
negatively  affects balance and posture. N abixim ols m ay also be effective in  disturbance 
of the norm al b ladder function, w hich  is com m on in  this condition [109]. The effects of 
individual cannabinoids on pain and m uscle spasticity in SM patients are shown in Table 5 .
Table 5. Cannabinoid therapies and their impacts on the symptoms of multiple sclerosis determined 
in clinical trials [109]. f.: decrease.
The Form Effects on Symptoms
smoked marijuana spasticity f , pain f
nabiximols spasticity f , pain f
oral Cannabis extract muscle spasticity f
dronabinol spasticity f ,  pain f
nabilone (+gabapentin) pain f
Studies of the use o f m edical m arijuana in  the treatm ent o f SM  suggest a reduction 
in spasticity after using phytocannabinoids, but it is not statistically significant. However, 
there w as a clin ically  significant subjective reduction in spasticity  reported by  patients. 
C annabinoids appear to be w ell-tolerated  by patients using them  as add-on therapy. It 
enables them to improve their score on the Ashworth Scale, which is a measure of spasticity 
by m easuring the resistance that occurs w hen soft tissue is passively stretched. However, 
m any studies give contradictory results, often  w ithou t statistical significance. U nfortu­
nately, the use o f Cannabis  harm s cognitive functions, and as m any as 40 -6 0 %  of SM  
patients suffer from it, so w hen starting cannabinoid therapy, the patient's cognitive func­
tions should be m onitored. M edical m arijuana has a positive im pact on SM  sym ptom s. 
However, m edical m arijuana does not slow  the disease's progression [56].
4.3. Vomiting and N ausea Prevention
Approxim ately 45-61%  of cancer patients suffer from chem otherapy-induced nausea 
and vom iting (CIN V). In antiem etic prophylaxis during chem otherapy, the follow ing are 
used: (i) drugs from  the group of 5 -H T 3 receptor antagonists— ondansetron, granisetron, 
tropisetron, dolasetron, palonosetron; (ii) drugs from  the group of neurokinin -1  receptor 
antagonists— aprepitant; (iii) corticosteroids— the m ost com m only recom m ended dex- 
am ethasone or m ethylprednisolone; and (iv) com plem entary drugs: dopam ine receptor 
antagonists (metoclopram ide), phenothiazine derivatives (chlorpromazine), antihistamines, 
and butyrophenone derivatives (haloperidol and droperidol) [112]. The guidelines propose 
the use of antiem etic drugs in m onotherapy or according to a schedule of tw o-to-three 
drugs, depending on the degree of risk of nausea and vom iting and the individual sensitiv­
ity of the patient. If the antiem etic prophylaxis proves ineffective, additional antiem etic 
drugs are used w hen needed. A n acute episode due to the stim ulation of gastrointestinal
receptors occurs up to 24 h after the initiation of chemotherapy, and delayed CINV occurs 
w ith in  o n e-fiv e  days, m ainly  due to the activation of receptors located in the brain. Sta­
tistically, the delayed effect is m ore frequent, and the incidence of nausea outw eighs the 
incidence of vom iting [113].
A ccording to studies, the incidence of nausea and vom iting  can be reduced by  acti­
vating the C B! receptor w ith THC [113]. As a result of receptor stim ulation, the proemetic 
effects of dopam ine and serotonin are abolished [114]. In the fight against CINV, oral 
cannabinoid preparations are m ore effective than a placebo. H ow ever, com pared w ith  
other antiem etics, studies lead to different conclusions. Som e of them  suggest the supe­
riority  of T H C , others, a sim ilar effectiveness, and still others show  that the best effect is 
obtained w hen com bining traditional drugs w ith cannabinoids [110] .
After reviewing random ized controlled trials, the conclusions are that adm inistering 
cannabinoids to patients during chem otherapy allow s for 70% control of nausea and 
6 6 % control of vom iting, w hile, after adm inistration of a placebo, the results reached 
57%  and 36% , respectively  [115] . D uring the research carried ou t in the seventies and 
eighties, TH C 's superiority  in the prevention of nausea and vom iting occurring during 
radio- and chem otherapy over the placebo and antiem etic drugs used at that tim e w as 
found. Currently, how ever, w e are already in  possession of m ore effective drugs for this 
indication. The com parisons show that newer drugs can control nausea in 90%  of patients, 
com pared to 30%  w ith  cannabinoids. For this reason, they are not used in the first line of 
treatm ent but only as an adjunct or second-line treatm ent [116]. Cesamet® or Marinol® can 
be used in the treatm ent of CIN V [56].
4.4. Pain
The endocannabinoid system is involved in pain control, and therefore, Cannabis may 
be used to relieve it [56]. The m ost com m on m edical use of Cannabis is pain m anagem ent, 
bu t it is not equally  effective for all types of pain. M ost likely, it results from  different 
m echanism s of pain form ation. Studies show that cannabinoids cannot com bat acute pain, 
bu t they can only relieve chronic pain  to a lim ited extent [33]. The pharm acotherapy of 
chronic pain is incredibly difficult, as is the pain that continues despite the tissue's healing.
Neuropathic pain is a type of chronic pain that occurs following damage to the periph­
eral or central nervous system . It appears as a result of an injury, disease, cancer, im m une 
disorder, or an  effect of certain  drugs. O ften, patients then experience allodynia, hyper­
algesia, depression, sleep problem s, and anxiety, and their contact w ith  society is usually 
lim ited . A ccording to Special Interest G roup on N europathic Pain, the guidelines for the 
treatm ent of neuropathic pain include: (i) first-line therapy: gabapentinoids— gabapentin 
and pregabalin, tricyclic antidepressants— am itriptyline, and serotonin-norepinephrine re­
uptake inhibitors— duloxetine and venlafaxine; (ii) second-line therapy: opioids— tramadol 
and tapentadol and topical treatm ent— lidocaine and capsaicin; and (iii) third-line therapy: 
strong opioids— m orphine and oxycodone and a neurotoxin— botulinum  toxin [117]. Due 
to the side effects of using available drugs in the treatm ent of neuropathic pain, and the fact 
that m ore than 50%  of people do not achieve the expected im provem ent, new therapeutic 
agents are sought continuously [118].
4.5. Increasing Appetite
A norexia m ay appear in the course of such chronic diseases as A ID S, cancer, or 
anorexia nervosa [56]. Progestational agents (m egestrol) are often used to increase the ap­
petite, and in the short-term, the use of corticosteroids, the oral ghrelin mimetic anamorelin, 
can be used [119]. H ow ever, there are m any lim itations to their use. H orm onal m anip­
u lation m ay be contraindicated in m any patients, and long-term  corticosteroid therapy 
m ay lead to m etabolic changes, m ore fractures, cataracts, gastrointestinal discom fort, and 
changes in mood or behavior. Seven patients w ith hematogenous metastatic melanoma and 
liver m etastases suffering from  extensive loss of appetite and nausea w ere adm inistered 
dronabinol (synthetic delta-tetrahydrocannabinol) capsules for four w eeks [120]. M ost
of the patients reported increased appetite and decreased nausea. These results lasted 
for several w eeks. A  m ore extensive, random ized study show ed that oral D ronabinol 
could help stim ulate appetite in advanced cancer patients and slow w eight loss. The study 
involved 469 people who had lost w eight due to advanced cancer. They were divided into 
three groups. The first received 5 m g of D ronabinol daily, the second 800 m g of m egestrol 
daily, and the third received both drugs. In  the group of people receiving only m egestrol, 
their appetite w as increased by  75% , w hile their w eight by  11%. In those receiving only 
Dronabinol, these values were 49%  and 3% , respectively, and these differences w ere statis­
tically  significant. O n the other hand, the adm inistration of both  drugs did not provide 
additional benefits. N um erous animal studies have also confirm ed an increase in appetite 
and the am ount of food consum ed after the adm inistration of cannabinoids. Studies in 
the 1970s show ed that sm oking m arijuana increases the num ber of calories you  eat. It 
seems crucial that, in people affected by cancer, medical m arijuana will have antiemetic and 
appetite-increasing effects [31]. Marinol® has been approved as a drug increasing appetites 
in patients w ith A ID S and cancer [116].
Cannabinoids have been established as possible for use in the third line of neuropathic 
pain treatm ent, right after antidepressants, anticonvulsants, and opioids. H ealth Canada 
has also im plemented guidelines recommending Cannabis smoking to com bat noncancerous 
chronic pain. Ultim ately, it w as established that there is substantial evidence of a positive 
effect of Cannabis  use in  chronic pain patients [33]. The best results in the treatm ent of 
neuropathic pain are achieved w ith low doses of T H C /C B D  or high doses of CBD  [118].
4.6. Inflam m atory Bowel Diseases
Inflammatory bowel diseases include ulcerative colitis and Crohn's disease. Although 
the etiology of these diseases has not been elucidated so far, it is assumed that directing the 
hum an im mune system against its own intestinal microflora contributes to their formation. 
In C rohn 's disease, conventional m edication includes am inosalicylates, corticosteroids, 
thiopurines, m ethotrexate, and thalidom ide. A ntitum or necrosis factors (inflixim ab, adal- 
im um ab, and certolizum ab) and other biologics such as antibodies (vedolizum ab and 
ustekinum ab) are also used [121] .
The endocannabinoid system is probably responsible for m aintaining intestinal hom e­
ostasis, because w hen disturbances occur, it triggers the synthesis of effector m olecules so 
that it m ay be involved in  intestinal inflam m ation. The presence of the endocannabinoid 
system  w ith in  the entire gastrointestinal tract has also been  dem onstrated. Cannabis has 
been  used in enteritis since ancient tim es, bu t unfortunately, research into its use in this 
indication is rare. Survey studies have shown that patients use Cannabis to self-m edicate to 
relieve inflam m atory bow el d isease sym ptom s such as abdom inal pain, loss of appetite, 
and diarrhea. Unfortunately, m ost studies are characterized by insufficient statistical signif­
icance and a problem w ith the selection of an appropriate placebo, as the effects of Cannabis 
on the central nervous system  are difficult to m ask [122] .
In an anonymous survey, IBD patients reported that Cannabis relieved abdominal pain 
(83.9% ), abdom inal cram ps (76.8% ), arthralgia (48.2% ), and, to a lesser extent, diarrhea 
(28.6%) [123]. A prospective, placebo-controlled study w as conducted to test the ability of 
Cannabis to remission Crohn's disease. The study involved 21 patients who did not respond 
to standard treatm ent, and their Crohn's disease activity index (CDAI) w as over 200. In the 
study group, patients received a cigarette containing 115 m g of TH C  twice a day, while, in 
the second group, patients received a placebo in the form  of TH C -free Cannabis flow ers. 
Their conditions were assessed during the eight-week treatm ent and, also, two weeks after 
its com pletion. Forty-five percent (5 /1 1 )  of the test group achieved com plete rem ission 
(CDAI decrease <150), w hile, in the placebo group, this effect w as found in 10% (1 /10 ) of 
people. In contrast, a decrease in  the C D A I score by  a m inim um  of 100 w as observed in 
10/11  people receiving Cannabis and 4 /1 0  in the placebo group. It is also worth noting the 
lack of reported adverse effects of the applied treatm ent [124].
4.7. Parkinson's Disease
Parkinson's disease is a neurological condition involving the degeneration of nigros- 
triatal dopam ine neurons. The disease's sym ptom s are prim arily m uscle stiffness, trem or 
at rest, bradykinesia, and lack of postural stability. A dditionally, depression, anxiety, or­
thostatic hypotension, constipation, fatigue, and sleep problem s m ay appear. M odern 
pharm acotherapy consists of supplem enting the deficiency of dopamine and symptomatic 
treatm ent. In patients w ith  Parkinson 's disease, treatm ent is sym ptom atic and focuses 
on im proving the m otor and nonm otor sym ptom s [125]. N o disease-m odifying drugs 
are available. D rugs that affect the m otor im pairm ent include levodopa, dopam ine ago­
nists (ropinirole and pram ipexole), m onoam ine oxidase inhibitors (selegiline and rasag- 
iline), catechol-O -m ethyltransferase inhibitors (entacapone), anticholinergic drugs (tri­
hexyphenidyl), and choline inhibitors. D epending on the sym ptom s, antipsychotics or 
antidepressants are also used . A ccording to this procedure, positive effects on the m otor 
sym ptom s are obtained, but also, side effects, such as dyskinesia, appear. For this reason, a 
solution that would holistically approach the treatm ent of this disease is continuously being 
sought. C om ponents of the endocannabinoid  system  are involved in regulating m otor 
functions and dopam ine activity. Therefore, Cannabis seem s to be an attractive therapeutic 
option in the treatm ent of m ovem ent and neurodegenerative disorders [126]. Studies have 
found m edical m arijuana to help com bat Parkinson's disease's m otor sym ptom s, such as 
stiffness, trem ors, and bradykinesia. In addition, it provides pain relief and reduces sleep 
disturbance in patients [127].
4.8. Tourette's Syndrome
Tourette's syndrom e's m ain sym ptom s are num erous m otor tics and the presence of 
at least one vocal tic. This disease affects approxim ately  1% of the population, and m en 
are affected by  the d isease three-to-four tim es m ore often than w om en. The therapy of 
Tourette's syndrom e m ay consist of neuropsychological interventions; pharm acotherapy: 
(i) drugs that b lock  or lessen dopam ine— haloperidol and risperidone, (ii) botulinum  
in jections, (iii) attention-deficit hyperactiv ity  disorder m edications— m ethylphenidate 
and dextroam phetam ine, (iv) central adrenergic inhibitors— clonidine and guanfacine, (v) 
antidepressants— fluoxetine, and (vi) antiseizure m edications: topiram ate; and deep brain 
stim ulation [128].
The treatm ents available today often fail to give the desired results or cause serious 
side effects, and m any patients are looking for alternatives or additive supplem ents to 
their standard therapy to relieve their symptoms [129]. They reach for dietary supplements 
or stim ulants such as alcohol, nicotine, or m arijuana, am ong others. Two patients using 
Sativex® show ed a clear im provem ent in m otor and vocal tics [56]. However, there is still 
very limited evidence for TH C's efficacy in relieving the symptoms of Tourette's syndrome, 
only from sm all clinical trials [130].
4.9. Schizophrenia
Schizophrenia is a m ental illness em erging m ost frequently in early adulthood. It 
involves so-called positive and negative symptoms and cognitive dysfunction. The positive 
sym ptom s include hallucinations, paranoia, and delusions, w hile the negative sym ptom s 
include em otional w ithdraw al, lack of m otivation, and decreased affect. The m ain drugs 
in the treatm ent of schizophrenia are antipsychotics (neuroleptics): (i) first generation—  
haloperidol, perazine, and chlorpromazine; (ii) second generation— olanzapine, quetiapine, 
and risperidone; and (iii) third generation— aripiprazole, brexpiprazole, and cariprazine. 
C om plem entary, non-neuroleptic drugs are also used— antidepressants, sedatives, hyp­
notics, and mood stabilizers [131].
Studies have shown an increased use of m arijuana in people w ith schizophrenia from 
the general population. It has been proven that these patients' endocannabinoid system s 
are disrupted. The num ber of their CB1 receptors is increased. Besides, consuming Cannabis 
sp. elevates the risk  of developing schizophrenia. Their harm fulness, how ever, depends
on the content of TH C  and C BD , because TH C  prom otes psychosis w hile C BD  has an 
antipsychotic effect. The long-term  use of Cannabis disrupts neuronal synchronization 
in a sim ilar w ay to people w ith  schizophrenia. Cannabis  adversely  affects the positive 
sym ptom s, and its use leads to m ore frequent relapses of the d isease after achieving 
remission. However, according to Cannabis use, an im provem ent in the negative symptoms 
w as found [109].
4.10. Glaucoma
G laucom a is an eye disorder characterized by  optic neuropathy w ith  visual field 
loss. It is often accom panied by  increased pressure in  the eyeball and results in the irre­
versible decrem ent of vision. G laucom a can be treated w ith m edication (eye drops), laser 
therapy, or surgery. The eye drops used : beta blockers— tim olol, levobunolol, and carte­
olol; prostaglandins— latanoprost, travoprost, and tafluprost; alpha-adrenergic agonists—  
brim onidine and apraclonidine; carbonic anhydrase inhibitors— dorzolam ide and brinzo- 
lam ide; and cholinergic drugs— pilocarpine and carbachol [132].
Studies using oral, intravenous, and inhaled m edical m arijuana have show n that 
A9-THC reduces the intraocular pressure, which is a risk factor for glaucoma. The patients 
(60-65% ) experience a 25%  reduction in  intraocular pressure [133]. M oreover, TH C  has 
been  show n to have neuroprotective potential [134]. The intraocular pressure low ering 
effect is probably related to the reduction of w ater production. H ow ever, this condition 
does not last long, necessitating frequent administration of the drug. Another disadvantage 
is the b lood pressure reduction of m arijuana and its potential ability  to reduce ocular 
perfusion [135]. There have also been  studies using TH C  in the form  of eye drops, bu t 
these w ere less effective. This approach w ould avoid system ic side effects but require the 
developm ent of a m ore effective delivery system  [133]. U nfortunately, the advantage of 
marijuana in terms of safety and effectiveness over currently available glaucoma treatments 
has not been dem onstrated so far [110 ].
4.11. CO VID-19
A t the end of 2019, the first-identified cases of a pneum onia of unknow n origin 
emerged from China. The N ational H ealth Com m ission of China reported on the epidemic 
in early  2020 [136]. Initially, the virus w as called "n ov el coronavirus 2 019" (2019-nC oV) 
by the W orld H ealth  O rganization (W H O ), bu t the nam e w as changed to "severe acute 
respiratory syndrom e coronavirus 2 "  (SARS-CoV-2) by  the international com m ittee of the 
C oronavirus Study Group (CSG), w hile the disease w as designated "coronavirus disease 
2019" by the W H O [137]. This virus is very contagious and has rapidly spread globally. On 
11 M arch 2020, the epidemic of COVID -19 disease caused by the SARS-CoV-2 coronavirus 
w as declared a pandem ic by  the W H O . U ntil then, m ore than 118,000 people across 
114 countries, territories, and areas w ere infected by this virus [138]. D uring treatm ent, 
already know n drugs are being used. N either a vaccine nor a specific cure has been 
developed yet [139].
The virus is transm itted directly from hum an-to-hum an (via coughing, sneezing, and 
the spread of respiratory droplets or aerosols) or indirectly (via contam inated surfaces). 
Therefore, isolation is a crucial elem ent in slowing down the spread of the novel virus [138]. 
Patients go through infection w ith varying severity, from asymptomatic to mild symptoms 
through severe stages to fatal cases. According to estim ates, approximately 70%  of COVID- 
19 patients are asym ptom atic or w ith  m ild disease, w hile the rem aining 30%  are severe 
cases [140]. The disease progression m ay depend on the patient's genetic differences in the 
im m une system  and the individual's exposom e [141].
A  m ild course of illness sym ptom s are cough, fever, headache, shortness of breath, 
m uscle pain, sore throat, diarrhea, vom iting, and the most characteristic loss of taste an d /o r 
smell [140]. In the severe disease, dyspnea appears, respiratory frequency is > 3 0 /m in , and 
blood oxygen saturation (SpO2) is <93% . The percentage of oxygen supplied is (fraction of 
inspired oxygen, FiO 2) <  300, a n d /o r  lung infiltrates are >50%  w ithin  24  to 48 h. Severe
pneum onia, A cute R espiratory D istress Syndrom e, as w ell as extrapulm onary sym ptom s 
and system ic com plications such as sepsis and septic shock are observed in patients
In the case of critically  ill patients, high concentrations o f interleukins (ILs)— IL-2, 
IL-7, and IL-10; granulocyte colony-stim ulating factor (G-SCF); monocyte chem oattractant 
protein-1 (M C P1/C CL2); macrophage inflammatory protein 1 alpha (M IP1-a/C C L 3); CXC- 
chemokine ligand (CXCL10/IP10); tumor necrosis factor (TN F-a); C-reactive protein (CRP); 
ferritin; and D-dim ers in SARS-CoV-2 are observed in patients' plasma [142]. The disease's 
high severity is related to the cytokine storm , w hich is possibly induced by the interleukin-6 
amplifier [143]. Respiratory failure, septic shock, an d /o r dysfunction or failure of multiple 
organs appear in the critical disease [144].
The m echanism  of SARS-CoV-2 attacking hum an cells is sim ilar to that of SARS-CoV. 
Coronavirus proteins bind to angiotensin-converting enzyme 2 (ACE2) receptors, w hich al­
lows them  to introduce into the host's cells viral RNA [145]. Extracts w ith a high content of 
CBD show the ability to downregulate enzymes: ACE2 and transmembrane serine protease 
2 (TMPRSS2), w hich makes SARS-CoV-2 challenging to enter the hum an body through oral 
airways [146,147]. Therefore, it could be used as a prophylaxis before COVID-19. Cannabid­
iol exhibits direct antioxidant activity by influencing the level and activity of antioxidants 
and oxidants. It  decreases reactive oxygen species (R O S) generation. M oreover, it affects 
the redox balance according to indirect m echanism s like the m odulation of CBD , PPAR-y, 
G PR 55, and TRP channel receptors 5-H Txa [148]. M oreover, C BD  as a PPA R-y agonist 
causes pulm onary inflammation limitation, a decrease of fibrosis, and the inhibition of viral 
replication and im m unom odulation. C BD  also has anti-inflam m atory properties due to 
the inhibition of cytokine production: IL -1a  and ß, IL-2, IL-6, interferon-gam m a, inducible 
protein-10 , m onocyte chem oattractant protein-1, m acrophage inflam m atory protein -1  a , 
and T N F -a  [149- 151]. Cannabis constituents THC and CBD also inhibit T-helper type 1 (Th1) 
cytokines an d /o r promote an in vitro and in vivo Th2 immune response [152]. Th1 and the 
inflam m atory im mune response profile predominate in COVID-19. Some viruses may take 
advantage of host inflammation, and others may be detrimental to host inflammation [152]. 
In COVID-19, hyperinflam m atory im m une responses can have serious consequences, such 
as increased disease severity and p atients' m ortality. Therefore, the im m unom odulatory 
effects of cannabinoids can help reduce the severity of sym ptom s. H ow ever, it should be 
rem em bered that Cannabis is an unconventional im m unom odulatory  agent. Its route of 
adm inistration through sm oking is contraindicated in  patients suffering from  C O V ID -19. 
Therefore, inhalation (extracts) or oral adm inistration should be considered to increase 
patient safety [152]. U nfortunately, there is no reliable evidence in hum ans confirm ing 
effective anti-inflam m atory doses for CBD  [153].
5. C onclu sions
The com plexity  of the p lant m atrix represented by Cannabis sp. m akes it possible to 
discover prototypes of m any com pounds that w ill show  pharm acological activity w ithin 
the endocannabinoid  system  or already show  activity  against receptors for w hich  the 
participation and mechanisms of action in the stim ulation of selected biochemical processes 
have been  confirm ed. To achieve the therapeutic goal, it is also essential to obtain  the 
appropriate bioavailability of the com pounds at the site of action. In the case of Cannabis , 
it is possible due to the synergism  of phytocannabinoids and terpenes absorption. The 
various pharmacological actions for selected combinations of chemical compounds present 
in Cannabis presented in this review constitute an argument for clinical effectiveness based 
on a m ulti-fragm ent affinity for m ultiple receptors. Therefore, the necessity  to search for 
new  indications of the pharm acological application of C annabis products is justified w ith 
regards to the search for target points within the endocannabinoid system and outside of it. 
H ow ever, it should be taken into account that the "entou rage effect" of the com pounds 
present in Cannabis raw materials will always be an im portant variable for the effectiveness 
and safety of therapy w ith their use.
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ACE2 angiotensin-converting enzyme 2
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CDAI Crohn's disease activity index
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COVID-19 coronavirus disease 2019
CRP C-reactive protein
CSG Coronavirus Study Group
CXCL10/IP10CYP CXC-chemokine ligandcytochrome P450
DMAPP dimethylallyl diphosphate
DS Dravet syndrome
FAAH fatty acid amide hydrolase




GPR G protein-coupled receptor
G-SCF granulocyte colony-stimulating factor
IBD inflammatory bowel disease
IL interleukin
IPP isopentenyl diphosphate
LD50LGS median lethal doseLennox-Gastaut syndrome
MCP1/CCL2 monocyte chemoattractant protein-1
MEP plastidic methylerythritol phosphate
MIP1-a/CCL3 macrophage inflammatory protein 1 alpha
MVA mevalonic acid
PPAR peroxisome proliferator-activated receptor
ROS reactive oxygen species
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SM sclerosis multiplex
SpO2Th1 blood oxygen saturationT-helper type 1
THC tetrahydrocannabinol
THCA tetrahydrocannabinolic acid
TMPRSS2 transmembrane serine protease 2
TNF-a tumor necrosis factor
TRPTRPM transient receptor potential channelstransient receptor potential melastatin
TRPV1 transient potential type 1 vanilloid receptor
TSC tuberous sclerosis syndrome
USP Pharmacopoeia of the United States
WHO World Health Organization
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